May 21, 2020
CytRx Corporation Highlights Latest Positive Event From its Licensed Drug Aldoxorubicin
Feb 28, 2020
CytRx Corporation Clarifies Certain Prior Disclosures Regarding its Relationship with Orphazyme A/S
Feb 28, 2020
CytRx Corporation Clarifies Certain Prior Disclosures Regarding its Relationship with Orphazyme A/S
Feb 11, 2020
CytRx Corporation Highlights Recently Published Data of its Licensee Orphazyme A/S Phase 2 Trial of Arimoclomol in the Treatment of Sporadic Inclusion Body Myositis (sIBM)
Feb 04, 2020
Immix Doses First Patient in USA in its Phase 1b/2a Trial in Patients with Advanced Solid Tumors
Feb 04, 2020
Immix Doses First Patient in USA in its Phase 1b/2a Trial in Patients with Advanced Solid Tumors
Dec 19, 2019
CytRx Corporation Highlights Significant Positive Events From its Two Licensed Drugs Arimoclomol and Aldoxorubicin
Aug 09, 2019
CytRx Corporation Reports Second Quarter 2019 Financial Results
Jul 22, 2019
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis
Jun 26, 2019
CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation
May 15, 2019
CytRx Corporation Reports First Quarter 2019 Financial Results
May 08, 2019
CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer
Apr 29, 2019
CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S
Mar 29, 2019
CytRx Corporation Reports 2018 Financial Results
Feb 13, 2019
CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR(TM) Technology Targeting Delivery Directly to the Tumor
Feb 11, 2019
CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for Chemotherapy
Jan 14, 2019
CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial
Dec 21, 2018
CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR(TM) Drug Candidates and Accompanying Companion Diagnostic
Nov 28, 2018
CytRx Corporation to Present at the 11th Annual LD Micro Main Event
Nov 08, 2018
CytRx Corporation Highlights NantCell Inc's Clinical Data with Aldoxorubicin Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting